Proprietary subcutaneous delivery platform. Lead program is exenatide, a transformational once- or twice-yearly treatment for type 2 diabetes. Clinical stage. Boston, MA
Acquired by Cytyc Corp. Diagnostics for women’s health. Sunnyvale, CA NASDAQ: ADZA
Commercializing non-invasive tests for transplant and autoimmunity Brisbane, CA NASDAQ: CDNA
Producer of drug discovery tools. Wilmington, MA NASDAQ: CRL
Acquired by Quest Diagnostics Diagnostic and database services and products for infectious and immunological diseases. Herndon, VA
Recent Comments